Allogene Therapeutics, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for ALLO, updated each market day.
ALLO AI Sentiment
AI sees no strong directional signal for Allogene Therapeutics, Inc. Common Stock stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Allogene Therapeutics, Inc. Common Stock
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).
Sector
Exchange
Market Cap
$709,393,747
Cap Tier
Employees
152
Headquarters
SOUTH SAN FRANCISCO, CA
Listed Since
Oct. 11, 2018
Website
ALLO Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
ALLO Volatility
Allogene Therapeutics, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
